AREV.F Stock Overview
Operates as an early-stage life science discovery company in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
AREV Life Sciences Global Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.01 |
| 52 Week High | CA$0.10 |
| 52 Week Low | CA$0.0002 |
| Beta | 2.47 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 203.03% |
| 33 Year Change | -91.76% |
| 5 Year Change | -97.38% |
| Change since IPO | -99.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| AREV.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.09% | 0.4% |
| 1Y | 203.0% | 19.0% | 32.6% |
Return vs Industry: AREV.F exceeded the US Pharmaceuticals industry which returned 19% over the past year.
Return vs Market: AREV.F exceeded the US Market which returned 32.6% over the past year.
Price Volatility
| AREV.F volatility | |
|---|---|
| AREV.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AREV.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AREV.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Mike Withrow | www.arevlifesciences.com |
AREV Life Sciences Global Corp. operates as an early-stage life science discovery company in Canada. It is involved in the extraction of compounds for consumption and topical use; clinical nutrition business; and Medicine Merchant, a technology platform. The company’s pipeline products include SUS-TAINN, a superior utility supplementation therapeutic agent for indicated nutritional needs; and RES-TORE, a product based on organic plant nutrition for patients with overt clinical need for rational enhanced caloric intake and micronutrient supplementation.
AREV Life Sciences Global Corp. Fundamentals Summary
| AREV.F fundamental statistics | |
|---|---|
| Market cap | US$2.11m |
| Earnings (TTM) | -US$239.54k |
| Revenue (TTM) | US$7.21k |
0.0x
P/S Ratio0.0x
P/E RatioIs AREV.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AREV.F income statement (TTM) | |
|---|---|
| Revenue | CA$7.21k |
| Cost of Revenue | CA$19.97k |
| Gross Profit | -CA$12.76k |
| Other Expenses | CA$226.78k |
| Earnings | -CA$239.54k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0075 |
| Gross Margin | -177.06% |
| Net Profit Margin | -3,322.80% |
| Debt/Equity Ratio | -12.5% |
How did AREV.F perform over the long term?
See historical performance and comparison